This analysis showed that, from 2009, over 94% of women diagnosed with invasive breast cancer had HER2 testing, following international standards and establishing the critical role of HER2 testing in guiding therapies offered to NZ women. This evidence concerns the gene ERBB2 and invasive breast carcinoma.